Wednesday, January 16, 2013
Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it completed a study testing radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral beta-amyloid in diagnosing Alzheimer's disease.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.